ATP6V0C is a core component of the V₀ domain of V-ATPase, a multi-subunit enzyme responsible for acidifying intracellular organelles (e.g., lysosomes, Golgi apparatus) by transporting protons across membranes . The V₀ domain consists of five subunits (a, b, c, c', d), where ATP6V0C forms the proteolipid c-ring, essential for proton translocation .
Recombinant bovine ATP6V0C is produced using diverse host systems:
Vectors: pCMV6-AC-GFP or similar plasmids with neomycin resistance for mammalian selection .
Tagging: C-terminal GFP or Myc-DDK tags for purification and localization studies .
ATP6V0C interacts with pyruvate kinase M2 (PKM2), enhancing aerobic glycolysis in esophageal cancer cells. Silencing ATP6V0C reduces lactate production, extracellular acidification, and PKM2 phosphorylation (Tyr105), impairing tumor growth .
Mutations in ATP6V0C (e.g., Ala22Thr) disrupt proton transport, leading to epilepsy and neurodevelopmental abnormalities. Functional studies in Drosophila and C. elegans show increased seizure-like behavior and reduced lifespan .
In neuroblastoma cells, ATP6V0C knockdown blocks lysosomal acidification, inhibiting autophagic flux and increasing α-synuclein and APP C-terminal fragment accumulation .
Stability: Recombinant ATP6V0C requires careful handling to maintain membrane-integrated conformation .
Functional Validation: Activity assays (e.g., LysoSensor fluorescence, V-ATPase inhibitor response) are critical for confirming functionality .
Therapeutic Potential: Targeting ATP6V0C in cancer or neurodegenerative diseases may leverage its role in pH regulation and metabolism .